The storied success of sildenafil has undeniably shaped the drug landscape. However, investing in companies heavily dependent on biosimilars and the diminishing patent protection surrounding this flagship https://active-bookmarks.com/story21280982/the-blue-pill-and-pharma-a-uncertain-investment